Superworth

REGENXBIO price to book ratio RGNX

Market value divided by the book value of the company's net assets, since 2015.

Today, Nov 2, 2026
6.6×
10-year median
2.9×
Against its 10-year history
92nd
percentile: 0 is its lowest day, 100 its highest
10-year range
1.0× to 34.2×
Peer median
4.9×

REGENXBIO's price to book ratio is 6.6× as of Nov 2, 2026.

That is above its ten-year median of 2.9×, higher than on 92% of days in the last ten years.

Over that time it ranged from 1.0× in Mar 2025 to 34.2× in Jul 2026.

The median for 4 biotech stocks of a similar size is 4.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far6.6×2.5×34.2×
20254.4×1.0×4.6×
20241.2×1.2×3.2×
20232.2×1.6×2.4×
20221.7×1.3×2.7×
20213.0×2.4×4.6×
20204.1×2.3×4.4×
20193.2×2.4×4.2×
20183.0×2.9×8.5×
20175.3×2.5×5.4×
20162.7×1.0×3.4×
20152.0×2.0×2.9×

Against its peers

Companies in Biotechnology nearest REGENXBIO's size, closest first, today.

CompanyPrice to book ratio
RGNXREGENXBIO6.6×
MGTXMeiraGTx4.2×
PLXProtalix BioTherapeutics2.9×
VCELVericel5.6×
ADMAAdma Biologics6.1×
Peer median4.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on REGENXBIO

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.